-transparent.png){kind=logo}
MDL 26,024GO was shown to be an orally absorbed mediator release inhibitor in the rat PCA and PPA tests. In addition, the compound was shown to both elicit and inhibit elicitation of the Bezold-Jarisch reflex in the dog. MDL 26,024GO also significantly reduced Ascaris-induced changes in pulmonary mechanics in cynomolgus monkeys. The compound inhibited both early and late phase antigen induced-changes in Ascaris-sensitive sheep, as well as the increased airway hyperreactivity which normally follows antigen challenge. These results suggest the compound may have therapeutic potential in the treatment of asthma.
Related Publications
L Baugh, and
W Abraham, and
E Matthews, and
P Lahr
November 2002,
Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
L Baugh, and
W Abraham, and
E Matthews, and
P Lahr
January 1990,
Pharmacology & toxicology,
L Baugh, and
W Abraham, and
E Matthews, and
P Lahr
September 1995,
The Journal of pharmacology and experimental therapeutics,
L Baugh, and
W Abraham, and
E Matthews, and
P Lahr
February 2007,
Inflammopharmacology,
L Baugh, and
W Abraham, and
E Matthews, and
P Lahr
August 1994,
Biochemical Society transactions,
L Baugh, and
W Abraham, and
E Matthews, and
P Lahr
January 1981,
Allergologia et immunopathologia,
L Baugh, and
W Abraham, and
E Matthews, and
P Lahr
January 1990,
Agents and actions,
L Baugh, and
W Abraham, and
E Matthews, and
P Lahr
January 2009,
Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
L Baugh, and
W Abraham, and
E Matthews, and
P Lahr
August 1990,
Transplantation proceedings,
L Baugh, and
W Abraham, and
E Matthews, and
P Lahr
September 1992,
Epilepsy research,
